Introduction
============

Neuroendocrine carcinomas (NECs) are a cluster of rare and heterogeneous neoplasms, and they are widely distributed throughout the whole human body, including the stomach, intestine, pancreas, adrenal, thyroid, breast, and among other areas.[@b1-ott-10-397],[@b2-ott-10-397] Most NECs occur in the gastroenteropancreatic system or respiratory tracts.[@b3-ott-10-397],[@b4-ott-10-397] The primary neuroendocrine breast carcinomas (NEBCs) are reported to have a very low incidence, accounting for \~1% of all breast carcinomas.[@b5-ott-10-397] Invasive breast carcinomas with neuroendocrine differentiation were first described by Feyrter and Hartmann in 1963;[@b6-ott-10-397] they found that this kind of breast carcinomas showed morphological features similar to neuroendocrine tumors of the gut and lung. In 1977, Cubilla and Woodruff reported the first series of primary carcinoid of the breast including 8 patients;[@b7-ott-10-397] this rare kind of cohort has been gradually increasingly recognized. In 2003, the World Health Organization (WHO) classification of breast tumors explicitly defined and classified NEBC; establishing that the neuroendocrine markers were detected by immunohistochemical staining in \>50% of the tumor cell population, is the unique requisite for the diagnosis of NEBC.[@b8-ott-10-397] The current 2012 WHO classification of tumors subdivides NEBC into 3 groups: well-differentiated neuroendocrine tumors, poorly differentiated NECs or small cell carcinomas, and invasive breast carcinomas with neuroendocrine differentiation.[@b9-ott-10-397] Due to the rareness of primary NEBC, most of the available knowledge was from case reports and reviews, very few were researches with small sample sizes.[@b7-ott-10-397],[@b10-ott-10-397]--[@b13-ott-10-397] In addition, a standard management of these tumors has not been established so far to date. Therefore, we present our own data about 19 NEBC patients including the clinical and pathological features, therapeutic strategies, and prognostic significance, hoping to contribute to offer more evidence for recognition of NEBC, especially for diagnosis, treatment, and prognosis.

Patients and methods
====================

Patients
--------

We retrospectively reviewed the medical records of the breast carcinoma patients who were diagnosed as breast carcinomas and had received treatment from 2005 to 2015 in The First Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China. Then, we allowed a series of patients confirmed to NEBC by histopathology to enroll in our analysis. Complete information of the NEBC patients, such as general information (including name, gender, age, and contact information), physical examination, imaging character, time of final diagnosis, surgical procedures, histopathology and immunohistochemistry characteristics, systemic adjuvant treatment, and follow-up outcome were collected by consulting the medical records and in consultation with the patients. This study was approved by the ethics committee from The First Affiliated Hospital of Chongqing Medical University, who deemed written informed consent not necessary due to the retrospective nature of the research.

Diagnostic
----------

The mammography and ultrasonography of breast were performed for further diagnosis. All lesions were diagnosed as Breast Imaging-Reporting and Data System category 5. Several cases had other imaging examinations such as magnetic resonance imaging (MRI) or positron emission tomography-computed tomography (PET-CT). However, the gold standard for diagnosing NEBC was histopathology, including the core biopsy, intraoperative frozen, and postoperative pathological examination.

Surgical procedures
-------------------

The surgical procedures included the breast-conserving surgery, the radical mastectomy, and the modified radical mastectomy. In addition, patients were staged according to the seventh edition of the AJCC Cancer Staging Manual.[@b14-ott-10-397]

Immunohistochemistry
--------------------

The histological slides were reviewed and classified according to the 2012 WHO classification.[@b9-ott-10-397] Several important indexes that were correlated with breast cancer, such as estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER-2), Ki-67 proliferation index, and oncoprotein P53, were detected by immunohistochemical staining. ER and PR were considered positive if \>1% of tumor cells were stained, and HER-2 was considered positive if immunohistochemical staining was 3+. Overexpression of *HER-2* genes in fluorescent in situ hybridization (FISH) was also identified as HER-2 positive. Ki67 was identified as highly expressed if \>14% tumor cells were stained. We also investigated the expression of the neuroendocrine markers by immunohistochemical staining, including chromogranin A (CgA), synaptophysin (Syn), neuron-specific enolase (NSE), and CD56. At least one mentioned neuroendocrine marker was positive in immunohistochemical staining.[@b8-ott-10-397]

Adjuvant therapy and follow-up
------------------------------

For patients enrolled in our analysis, we got their detailed treatment strategy and follow-up information by contacting them and consulting the medical records. We mainly got the information about whether they had comprehensive treatments, including operation, chemotherapy, radiotherapy, and/or endocrine therapy, and whether regular follow-up was carried out to assess the prognosis conditions.

Results
=======

The clinical characteristics of all primary NEBC patients at diagnosis
----------------------------------------------------------------------

From 2005 to 2015, a total of 19 NEBC patients meeting the diagnostic criteria were enrolled in our study for further analysis. All patients were women, and the median age was 61 years (ranging from 17 to 82 years, mean age 59.2 years). All patients visited our hospital due to a palpable breast mass, and then they carried out several assistant examinations for further diagnosis, such as mammography and breast ultrasonography. The lump sizes ranged from 8 to 150 mm in greatest dimension. The location appeared in the left breast in 11 patients (57.9%) and right breast in the remaining 8 patients (42.1%). They were finally diagnosed as NEBC by pathological examination. Of these patients, 18 NEBC patients were operable and underwent operation as soon as they were confirmed; 1 patient without surgery was found to have distant metastasis at diagnosis. Among these surgery patients, only 4 of 18 patients had axillary lymph node metastasis, and the metastasis rates were 2/15, 2/16, 11/12, and 4/13, respectively. According to the pathological tumor node metastasis (pTNM) staging system of AJCC,[@b14-ott-10-397] except for 1 patient who was unable to be staged because her breast mass was removed outside of our hospital and we failed to get her initial clinical data, 1 patient with distant metastasis at diagnosis was stage IV, 2 of 19 patients were stage III and the residual 15 patients were stage I to II ([Table 1](#t1-ott-10-397){ref-type="table"}).

The immunohistochemical of all primary NEBC patients
----------------------------------------------------

Except 4 patients who were unknown about the status of ER and PR, of the remaining included 15 NEBC patients, ER was expressed in 14 patients (93.3%) and PR was expressed in 11 patients (73.3%). No available data showed HER-2 was positive in immunohistochemistry or FISH. Ki67 was highly expressed (\>14%) in 4 of 10. For neuroendocrine markers, all 19 patients had detected CgA, while only 18 patients had detected Syn, 14 patients had detected NSE, and 6 patients had detected CD56. As a result, 8 of 19 (42.1%) were CgA positive, 14 of 18 (77.8%) were Syn positive, 12 of 14 (85.7%) were NSE positive, and 2 of 6 (33.3%) were CD56 positive, as listed in [Table 2](#t2-ott-10-397){ref-type="table"}.

Adjuvant therapy
----------------

For 18 operable patients, only 1 case with local advanced disease received neoadjuvant chemotherapy in order to reduce the lesions' size and remove all lesions successfully, so that they could get a long-term local control ([Table 3](#t3-ott-10-397){ref-type="table"}). The one stage M1 also received neoadjuvant chemotherapy. In addition, apart from 2 patients without information of postoperative therapy, 11 patients had undergone postoperative chemotherapy, while 5 patients older than 75 years did not receive chemotherapy on account of they were so old that they were difficult to endure postoperative chemotherapy. However, within these 11 patients who received postoperative chemotherapy, 2 patients did not finish the entire planned chemotherapy because of the unbearable adverse reaction. The specific chemotherapy program of every patient is listed in [Table 3](#t3-ott-10-397){ref-type="table"}.

For radiotherapy, only 3 of 19 patients were recommended; 1 of them was a young patient with multiple lesions and distant metastasis, 2 other patients were middle-aged women with \>3 lymph node metastasis, but we failed to collect radiotherapy data of one of them because we did not contact the patient ([Table 3](#t3-ott-10-397){ref-type="table"}).

By consulting the medical record and asking patients, we found that only 8 women received endocrine therapy and the selection of medicines depended on their menstrual status. In total, 1 patient was negative in hormone receptor and did not require endocrine therapy and 2 patients refused to receive endocrine therapy. The other 8 patients had no available endocrine therapy data ([Table 3](#t3-ott-10-397){ref-type="table"}).

Post-therapy surveillance and follow-up
---------------------------------------

With a median follow-up of 59.2 months (ranging from 15.5 to 114), 2 of the patients died due to nonbreast cancer causes, 7 patients were lost to follow-up, and the remaining 10 patients were still alive. Of the 10 alive women, 7 survived without recurrence and metastasis, 1 of 10 was staged M1 at the preliminary diagnosis, and only 2 of 10 cases progressed after systemic therapy.

One patient was a 58-year-old woman with disease of the right breast, and 11/12 confirmed axillary lymph node metastasis by surgery. She was readmitted to our hospital due to the abnormal central nervous system symptoms. The PET-CT scan recognized isolated occupied lesions at her left frontal lobe, without other suspicious lesions. Given her NEBC history that she was diagnosed before 3.6 years, she was highly suspected of brain metastases and received an operation to remove the intracranial tumor. Eventually, the postoperative pathological examination confirmed to be the metastatic NEC. After the operation, she has continued to take the medication of anastrozole, up to now, without new suspicious lesions.

Another patient was a 43-year-old woman who developed bone and hepatic metastases during the follow-up. Initially, she underwent a modified radical mastectomy with axillary lymph node dissection and a complete postoperative adjuvant chemotherapy. Subsequently, the patient continued with endocrine therapy until the ilium bone metastases were detected after a follow-up of 32 months. No evidence of additional suspicious lesion in the whole body was noted by PET-CT. The patient carried out 6 cycles of chemotherapy and local radiotherapy of the ilium, as well as diphosphonate for 1 year. Meanwhile, the endocrine therapy was continued. Unfortunately, over a period of 38 months, after she was confirmed as NEBC for 70 months, she undertook a spiral computed tomography (CT) of the abdomen ([Figure 1](#f1-ott-10-397){ref-type="fig"}), and the result revealed that the density of liver parenchyma was diffusely reduced, with extensive round-like higher density lesions in plain scan and multiple nodular enhancement in enhanced CT of the liver. Meanwhile, the blood tumor marker carcinoembryonic antigen (CEA) of this patient was significantly increased. A lot of evidence tended toward the diagnosis of hepatic metastases. For further treatment, an operation of ovarian ablation followed by anastrozole therapy was performed for her progressive disease, combined with capecitabine. After 7 months (in April 2013), the CT of the abdomen showed that the hepatic lesions noteworthy decreased ([Figure 2](#f2-ott-10-397){ref-type="fig"}), as well as the level of CEA due to the effect of anastrozole and capecitabine therapy, and hence, the therapy was continued. The reinspection of CT of the abdomen and circulating CEA in May 2014 suggested an improvement of the patient's disease ([Figure 3](#f3-ott-10-397){ref-type="fig"}). However, in October 2014, the patient was readmitted to our hospital because of advance of the bone and hepatic metastatic lesions ([Figure 4A and B](#f4-ott-10-397){ref-type="fig"}) and increase in the CEA. As a result, the patient received chemotherapy again, and the hepatic lesions had obviously narrowed after chemotherapy ([Figure 4C and D](#f4-ott-10-397){ref-type="fig"}). Later, capecitabine was used as maintenance therapy, and the disease in bone and liver was has been stable so far.

Discussion
==========

Primary NEBCs are an uncommon entity, and were first described by Feyrter and Hartmann in 1963.[@b6-ott-10-397] In spite of several sporadic reports, not until 2003 when the WHO defined and classified it, did the public have a real sense of recognition of NEBC. However, enhanced attention was paid to NEBC over the past few years; there were still some challenges in the management of NEBC, including the diagnosis, treatments, and long-term outcome.

Imaging examination such as mammography, ultrasonography, or MRI could provide some helpful imaging findings, but there was still a degree of difficulty in the diagnosis of NEBC by imaging examination; a number of NEBC patients appeared to have signs of common breast carcinomas such as ill-defined margins, irregular shapes, calcification, and so on, and other patients' breast carcinomas might show regular shapes and well-circumscribed margins just like benign lesions.[@b15-ott-10-397],[@b16-ott-10-397] As previously reported, the imaging characteristics of NEBC in our study were also variable on radiography ([Tables S1](#SD1-ott-10-397){ref-type="supplementary-material"} and [S2](#SD2-ott-10-397){ref-type="supplementary-material"}), but the majority of NEBC tended to present poor features in mammography or ultrasonography.

It is widely accepted that pathological examinations are gold standards for the diagnosis of carcinomas. Microscopically, the tumor cells in well-differentiated neuroendocrine tumors might present spindle and plasmacytoid appearances, occasionally with clear cell features, while the tumor cells in poorly differentiated NECs and small cell carcinomas might appear with high nuclear/cytoplasmic ratios, an active mitotic rate, smoky dense chromatin, areas of necrosis, and frequent lymphovascular emboli.[@b9-ott-10-397],[@b17-ott-10-397] However, primary NEBCs were not easily recognized initially just depend on routine microscopic morphology and immunohistochemistry features due to mixed growth patterns.[@b13-ott-10-397] Although the WHO Working Group defined NEBC as a unique cohort that showed morphological features similar to neuroendocrine tumors of the gastrointestinal tract and lung,[@b8-ott-10-397] a number of studies reported that some nonspecial or special breast carcinomas also presented neuroendocrine differentiation.[@b18-ott-10-397]--[@b20-ott-10-397] Furthermore, the 2012 WHO Working Group acknowledged that this 50% cut-off, which was a requirement in 2003, was conceptually arbitrary and reached an agreement on incorporating this group in NEBC without the requirement for expression of neuroendocrine markers in at least 50% of tumor cell population.[@b9-ott-10-397] Therefore, the current classification of NEBC is well-differentiated neuroendocrine tumors, poorly differentiated NECs or small cell carcinomas, and invasive breast carcinomas with neuroendocrine differentiation. This makes more challenging the diagnosis of NEBC especially for invasive breast carcinomas with neuroendocrine differentiation, and it suggests that particularly immunohistochemical staining for neuroendocrine markers including CgA, Syn, NSE, and CD56 is necessary for recognizing this infrequent type of breast carcinomas.[@b5-ott-10-397],[@b21-ott-10-397] In agreement with earlier studies, NEBC tended to present hormone receptors (ER and/or PR) and absent HER-2.[@b5-ott-10-397],[@b22-ott-10-397],[@b23-ott-10-397] However, positivity of ER and/or PR alone was not sufficient to confirm primary NEBC because the hormone receptors were not exclusive to the mammary gland.[@b24-ott-10-397],[@b25-ott-10-397] In the diagnosis of primary NEBC, metastasis NECs presenting as a breast lump should be excluded and an in situ component and/or positive immunohistochemical reactivity for CK7 and mammaglobin support a primary breast origin.[@b24-ott-10-397],[@b26-ott-10-397]--[@b28-ott-10-397]

Primary NEBCs were reported to be more common in elderly women.[@b5-ott-10-397],[@b10-ott-10-397],[@b29-ott-10-397],[@b30-ott-10-397] In our study, the age of NEBC patients ranged from 17 to 82 years, and the mean age was 59.2 years, which was in accordance with previous reports. All operable patients except the one who was stage M1 received surgery, and the benefits were obvious. Given still lack of a standard treatment protocol for this kind of uncommon carcinomas, current treatment protocol of primary NEBC was similar to that of invasive breast carcinomas.[@b10-ott-10-397],[@b12-ott-10-397],[@b22-ott-10-397],[@b29-ott-10-397] Surgery resection should always be considered as the first line of treatment. Endocrine therapy had been proved to be crucial to the hormone receptor-positive breast tumors, however, whether there was equally important effect of endocrine therapy for NEBC coming from a different origin, especially for NEBC patients with high expression of hormone receptor, was yet to reach a consensus. But several reports presented that these adjuvant systemic treatments including chemotherapy, radiotherapy, and endocrine therapy might play an important role and should be performed according to individuality of the patients with NEBC.[@b31-ott-10-397],[@b32-ott-10-397] Moreover, several publications reported that somatostatin and its analogs might be of help for primary NEBC with scintigraphic-confirmed somatostatin-receptor expression.[@b23-ott-10-397],[@b33-ott-10-397] But in our study, none of the patients received treatment of somatostatin and its analogs.

The prognosis of primary NEBC was equally inconsistent. Primary NEBCs were reported to be associated with worse long-term outcomes compared to primary invasive breast carcinomas.[@b12-ott-10-397] Similarly, a population-based study from the Surveillance, Epidemiology, and End Results (SEER) database showed that NEBCs were an aggressive breast carcinoma type with significantly shorter overall survival (OS) and disease-specific survival (DSS) than nonspecial invasive breast carcinoma.[@b30-ott-10-397] To the contrary, few studies demonstrated a better prognosis in NEBC patients.[@b21-ott-10-397],[@b34-ott-10-397],[@b35-ott-10-397] There was also some studies that showed no difference from other breast carcinomas with regard to prognosis and clinical presentation.[@b36-ott-10-397],[@b37-ott-10-397] Within our study, the number of patients with NEBC were too few to make a valuable survival analysis. However, for our included 10 patients with available clinical follow-up data, 70% patients were alive free of disease and 30% are alive well with tumor, which presents a better prognosis in accordance with previous reports. Besides, two patients with disease progression after initial treatment still obtained a good effect in metastasis diseases, and they all alive without further progression of the disease. The outstanding treatment effects of these 2 patients might prove a well prognosis for NEBC patients even if they had distant metastasis. It could also provide more experience in this unusual disease.

It is also undeniable that there are a few limitations in our study. On the one hand, we could not collect sufficient number of patients because of a lack of NEBC. On the other hand, some patients were lost to follow-up and some patients had poor treatment compliance, which led us to obtain fewer available data. Hence, we could not make a significant conclusion.

Conclusion
==========

NEBCs are a rare type of breast carcinomas and tend to occur in older women. They are more likely to be ER/PR positive and HER-2 negative. Particularly, immunohistochemical staining for neuroendocrine markers was extremely contributed to the confirmation of this uncommon cohort. The recognition of NEBC is limited, and the current treatment protocol is similar to general invasive breast carcinomas. Previous studies are still ambiguous with regard to the therapeutic regimen and long-term outcome. Our study retrospectively reviewed related literature and our own clinical information and summarized clinical features, therapeutic strategies, and prognostic significance of NEBC, which might be helpful to increase knowledge of NEBC. However, more evidence should be provided to enhance the understanding of diagnosis, treatment, and prognosis for NEBC.

Supplementary materials
=======================

###### 

Mammography features of NEBC

  Number   Presentation    Location   Shape         Margins         Density      Calcification   BI-RADS
  -------- --------------- ---------- ------------- --------------- ------------ --------------- ---------
  1        Mass            LUOQ       Round         Indistinct      High         Clustered       4C
  2        Mass            LUOQ       Round         Indistinct      High         None            4B
  3        Mass            LLOQ       Oval          Well defined    High         None            0
  4        Mass            LUIQ       Oval          Well defined    High         None            4B
  5        Nondetectable                                                                         0
  6        Mass            LLOQ       Irregular     Circumscribed   High         Micro           4A
  7        Mass            LU         Irregular     Indistinct      High         Micro           4C
  8        Nondetectable                                                                         
  9        Unknown                                                                               
  10       Distortion      RUOQ       Not obvious   Indistinct      Isodensity   Needle like     5
  11       Calcification   RUOQ       Not obvious   Not obvious     High         Sand like       6
  12       Mass            LUOQ       Irregular     Spiculate       High         None            5
  13       Not done                                                                              
  14       Mass            LUOQ       Irregular     Indistinct      High         Sand like       Unknown
  15       Mass            RUOQ       Lobulated     Spiculate       High         None            6

**Abbreviations:** NEBC, neuroendocrine breast carcinoma; BI-RADS, Breast Imaging-Reporting and Data System; LUOQ, left upper outer quadrant; LLOQ, left lower outer quadrant; LUIQ, left upper inner quadrant; LU, left upper; RUOQ, right upper outer quadrant.

###### 

Ultrasonography features of NEBC

  Number   Shape       Margins        Echogenicity    Calcification   Color Doppler              Lymph node enlargement
  -------- ----------- -------------- --------------- --------------- -------------------------- ------------------------
  1        Round       Indistinct     Hypoechoic      Punctiform      Increased blood supply     Yes
  2        Round       Indistinct     Hypoechoic      None            None                       No
  3        Oval        Well defined   Hypoechoic      None            High-velocity blood flow   Yes
  4        Oval        Well defined   Hypoechoic      None            High-velocity blood flow   Yes
  5        Irregular   Indistinct     Hypoechoic      None            None                       No
  6        Irregular   Indistinct     Heterogeneous   None            Increased blood supply     Yes
  7        Irregular   Spiculate      Heterogeneous   None            None                       No
  8        Irregular   Crab like      Heterogeneous   None            Increased blood supply     No
  9        Unknown                                                                               
  10       Lobulated   Indistinct     Heterogeneous   Clustered       Increased blood supply     Yes
  11       Oval        Indistinct     Heterogeneous   None            None                       Yes
  12       Irregular   Indistinct     Heterogeneous   Punctiform      Increased blood supply     Yes
  13       Not done                                                                              
  14       Irregular   Crab like      Heterogeneous   None            Increased blood supply     No
  15       Irregular   Crab like      Heterogeneous   Punctiform      Increased blood supply     No

**Abbreviation:** NEBC, neuroendocrine breast carcinoma.
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![CT image of the patient with hepatic metastasis in September 2012, 70 months after the initial surgical treatment.\
**Notes:** (**A** and **B**) The image of plain scan showed that the density of liver parenchyma was diffusely reduced, and extensive round-like higher density lesions in the liver. (**C** and **D**) Enhanced CT revealed multiple nodular enhancement in liver.\
**Abbreviation:** CT, computed tomography.](ott-10-397Fig1){#f1-ott-10-397}

![Post-therapy abdominal CT of the patient with hepatic metastasis in April 2013.\
**Note:** Over a period of 7 months of treatment, both (**A** and **B**) plain scan and (**C** and **D**) enhanced CT showed that the hepatic lesions were gradually decreased.\
**Abbreviation:** CT, computed tomography.](ott-10-397Fig2){#f2-ott-10-397}

![Post-therapy abdominal CT of the patient with hepatic metastasis in May 2014.\
**Note:** With 20 months of treatment, the hepatic lesions were further reduced in both (**A** and **B**) plain scan and (**C** and **D**) enhanced CT.\
**Abbreviation:** CT, computed tomography.](ott-10-397Fig3){#f3-ott-10-397}

![Surveillant CT.\
**Notes:** (**A** and **B**) The CT of the abdomen showed that the hepatic metastasis lesions of this patient progressed again in October 2014. (**C** and **D**) After a modified therapy, the reduction of hepatic lesions was obviously found by CT of the abdomen in February 2015.\
**Abbreviation:** CT, computed tomography.](ott-10-397Fig4){#f4-ott-10-397}

###### 

The clinical information of primary NEBC patients at diagnosis

  Number   Gender   Age (years)   Location   Diagnosis date, month/year   Single/multiple lesions   Tumor size (mm)         Surgical treatment                          Lymph node (LN)                                                   Stage
  -------- -------- ------------- ---------- ---------------------------- ------------------------- ----------------------- ------------------------------------------- ----------------------------------------------------------------- ---------
  1        Female   61            Left       01/2015                      Single                    14                      MRA + SLNB + ALND                           2/15                                                              II
  2        Female   77            Left       08/2015                      Single                    15                      MRA + ALND                                  0/11                                                              I
  3        Female   17            Left       06/2014                      Multiple (2)              33 and 18               No                                          Bilateral neck, left supraclavicular and mediastinum LN, pleura   IV
  4        Female   57            Left       03/2014                      Single                    35                      Mastectomy + SLNB                           0/1                                                               II
  5        Female   64            Left       03/2012                      Single                    16                      MRA + ALND                                  0/13                                                              I
  6        Female   65            Left       11/2011                      Single                    24                      MRA + ALND                                  0/18                                                              II
  7        Female   45            Left       11/2011                      Single                    8                       MRA + ALND                                  0/14                                                              I
  8        Female   46            Right      05/2011                      Single                    31                      MRA + ALND                                  2/16                                                              II
  9        Female   43            Right      10/2006                      Single                    30                      MRA + ALND                                  0/8                                                               II
  10       Female   58            Right      04/2009                      Single                    24                      MRA + ALND subcutaneous                     11/12                                                             III
  11       Female   41            Right      03/2010                      Multiple (3)              Max: 10                 Mastectomy + ALND + breast reconstruction   4/13                                                              II
  12       Female   79            Left       12/2009                      Single                    20                      MRA + ALND                                  0/11                                                              I
  13       Female   82            Right      07/2008                      Single                    130 (with ulceration)   Mastectomy                                  0/2                                                               III
  14       Female   53            Left       11/2007                      Single                    75                      MRA + ALND                                  0/17                                                              II
  15       Female   69            Right      05/2007                      Single                    15                      MRA + ALND                                  0/30                                                              I
  16       Female   77            Left       03/2008                      Single                    45                      MRA + ALND                                  0/17                                                              II
  17       Female   50            Right      06/2005                      Single                    15                      MRA + ALND                                  0/13                                                              I
  18       Female   65            Right      07/2005                      Single                    Unknown                 MRA + ALND                                  0/17                                                              Unknown
  19       Female   76            Left       12/2005                      Single                    50                      MRA + ALND                                  0/13                                                              II

**Abbreviations:** NEBC, neuroendocrine breast carcinoma; MRA, modified radical mastectomy; SLNB, sentinel lymph node biopsy; ALND, axillary lymph node dissection.

###### 

The immunohistochemistry of primary NEBC patients

  Number   ER     PR     HER-2/FISH   CgA   Syn    NSE    CD56   Ki67 (%)   P53 (%)
  -------- ------ ------ ------------ ----- ------ ------ ------ ---------- ---------
  1        P      N      (2+)/N       N     P      P      N      20         \<5
  2        P      P      N            P     P      N      N      5          N
  3        N      N      None         N     P      None   P      80         P
  4        P      P      N            P     P      None   N      3          N
  5        P      P      N            N     N      P      None   \<5        P
  6        P      P      (2+)/N       N     P      P      None   80         50
  7        P      P      (2+)/N       N     N      P      None   \<3        P
  8        P      P      N            N     P      P      None   50         5
  9        P      P      N            P     P      None   None   None       N
  10       P      N      N            P     P      None   N      None       N
  11       P      P      N            P     N      P      None   10         5
  12       P      P      N            N     P      P      None   5          N
  13       None   None   None         P     P      N      None   None       None
  14       P      P      (2+)/none    N     P      P      None   None       N
  15       P      P      N            P     P      P      P      None       N
  16       None   None   None         P     P      None   None   None       None
  17       None   None   None         N     None   P      None   None       None
  18       P      N      N            N     N      P      None   None       N
  19       None   None   None         N     P      P      None   None       None

**Abbreviations:** NEBC, neuroendocrine breast carcinoma; ER, estrogen receptor; PR, progesterone receptor; HER-2, human epidermal growth factor receptor 2; FISH, fluorescent in situ hybridization; CgA, chromogranin A; Syn, synaptophysin; NSE, neuron-specific enolase; P, positive; N, negative.

###### 

The adjuvant therapy and clinical follow-up of primary NEBC patients

  Number   Neochemotherapy   Chemotherapy                                          Radiotherapy   Endocrine therapy   Follow-up (months)   Recurrence and metastasis                                              Survival
  -------- ----------------- ----------------------------------------------------- -------------- ------------------- -------------------- ---------------------------------------------------------------------- ----------
  1        No                Yes, EC-T                                             Not required   No                  15.5                 No                                                                     Yes
  2        No                No                                                    Not required   Yes, exemestane     16.4                 No                                                                     Yes
  3        Yes, EP           No                                                    Yes            Not required        22.9                 Yes, bilateral neck, left supraclavicular and mediastinum LN, pleura   Yes
  4        No                Yes, TEC[\*](#tfn4-ott-10-397){ref-type="table-fn"}   Not required   Yes, letrozole      25.3                 No                                                                     Yes
  5        No                Yes, TC                                               Not required   Yes, anastrozole    49.5                 No                                                                     Yes
  6        No                Yes, TEC[\*](#tfn4-ott-10-397){ref-type="table-fn"}   Not required   Yes, anastrozole    53.6                 No                                                                     Yes
  7        No                Yes, TEC                                              Not required   Yes, tamoxifen      53.9                 No                                                                     Yes
  8        No                Yes, TT[\#](#tfn3-ott-10-397){ref-type="table-fn"}C   Not required   Yes, exemestane     59.4                 No                                                                     Yes
  9        No                Yes, TP                                               Not required   Yes, tamoxifen      114                  Yes, brain                                                             Yes
  10       Yes, TAC          Yes, TAC                                              Yes            Yes, anastrozole    85                   Yes, bone and liver                                                    Yes
  11       No                Yes, TEC                                              Unknown        Unknown             73.4                 Unknown                                                                Unknown
  12       No                No                                                    Not required   No                  57.7                 No                                                                     Death
  13       No                No                                                    Not required   Unknown             52.4                 No                                                                     Death
  14       No                Yes, CEF                                              Not required   Unknown             101.5                Unknown                                                                Unknown
  15       No                Yes, CT[\#](#tfn3-ott-10-397){ref-type="table-fn"}F   Not required   Unknown             107.3                Unknown                                                                Unknown
  16       No                No                                                    Not required   Unknown             Unknown              Unknown                                                                Unknown
  17       No                Unknown                                               Not required   Unknown             Unknown              Unknown                                                                Unknown
  18       No                Unknown                                               Not required   Unknown             Unknown              Unknown                                                                Unknown
  19       No                No                                                    Not required   Unknown             Unknown              Unknown                                                                Unknown

**Notes:**

T: pirarubicin (THP).

Not finished entire planned chemotherapy.

**Abbreviations:** NEBC, neuroendocrine breast carcinoma; E, epirubicin; C, cyclophosphamide; T, docetaxel; F, fluorouracil (5-Fu); P, cis-platinum; LN, lymph node.
